[-] Show simple item record

dc.contributor.authorJimenez, Julioeng
dc.contributor.authorSafranek, Saraheng
dc.date.issued2007-08eng
dc.description.abstractWhen used to delay the progression of early nephropathy in patients with type 2 diabetes mellitus, angiotensin receptor blockers (ARBs) are not superior to angiotensin-converting enzyme (ACE) inhibitors. (Strength of Recommendation: C, multiple randomized controlled trials [RCTs]).eng
dc.identifier.citationAmerican Family Physician, 76(3) 2007.eng
dc.identifier.urihttp://hdl.handle.net/10355/3984eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofClinical Inquiries, 2007 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjecttelmisartaneng
dc.subjectenalaprileng
dc.subjecturine albumin excretioneng
dc.subjectrenal functioneng
dc.subject.lcshAlbuminuriaeng
dc.subject.lcshDiabetes -- Complicationseng
dc.subject.lcshDiabetic nephropathieseng
dc.titleAngiotensin Blockade in Patients with Diabetic Nephropathyeng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record